about
RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunctionIntracerebral haemorrhage in Down syndrome: protected or predisposed?Lymphatic Clearance of the Brain: Perivascular, Paravascular and Significance for Neurodegenerative DiseasesClearance systems in the brain-implications for Alzheimer diseaseTowards understanding the roles of heparan sulfate proteoglycans in Alzheimer's diseaseEffect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (review)General anesthetics and β-amyloid proteinCurrent and future implications of basic and translational research on amyloid-β peptide production and removal pathwaysImpaired Aβ clearance: a potential link between atherosclerosis and Alzheimer's diseaseMultifaceted role of matrix metalloproteinases (MMPs)Suppression of Alzheimer's disease-related phenotypes by geranylgeranylacetone in miceA humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic miceMetformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice.Pyrrolidine dithiocarbamate attenuates brain Aβ increase and improves long-term neurological outcome in rats after transient focal brain ischemia.Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study.Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer's Disease.Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.gamma-Secretase dependent production of intracellular domains is reduced in adult compared to embryonic rat brain membranesAn association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3.1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patientsElevated Aβ42 in aged, non-demented individuals with cerebral atherosclerosis.Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathiesMatrix metalloproteinases and their multiple roles in Alzheimer's disease.Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease.Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease.Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cellsExpression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.Somatostatin modulates insulin-degrading-enzyme metabolism: implications for the regulation of microglia activity in ADIncreased tau phosphorylation and impaired presynaptic function in hypertriglyceridemic ApoB-100 transgenic miceThe absence of myelin basic protein promotes neuroinflammation and reduces amyloid β-protein accumulation in Tg-5xFAD mice.Alterations in gene expression in mutant amyloid precursor protein transgenic mice lacking Niemann-Pick type C1 proteinIncreased accumulation of intraneuronal amyloid beta in HIV-infected patients.Genetic association of urokinase-type plasminogen activator gene rs2227564 site polymorphism with sporadic Alzheimer's disease in the Han Chinese population.PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme.Insulin suppresses the expression of amyloid precursor protein, presenilins, and glycogen synthase kinase-3beta in peripheral blood mononuclear cells.Overexpression of the IGF-II/M6P receptor in mouse fibroblast cell lines differentially alters expression profiles of genes involved in Alzheimer's disease-related pathologyPKCε promotes HuD-mediated neprilysin mRNA stability and enhances neprilysin-induced Aβ degradation in brain neuronsCALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9.The influence of tumour necrosis factor- α (TNF-α) on amyloid-β (Aβ)-degrading enzymes in vitro.
P2860
Q24315809-618413B1-6670-4792-A28F-32FC30BDC86CQ26745369-EFFFCEBB-E0D3-4671-AE92-8BA62086A018Q26753215-35BC768A-321F-4655-A297-9804FF4362AFQ26801541-1398F357-AD2B-46FF-98B8-9A23C2D78070Q26992202-0D2BBB0A-3DBC-4FB4-B266-E1FC503E38AEQ27001244-7C7E8DFE-A675-4668-8284-5C51EA28A8D6Q27010208-D247037F-60ED-49BD-8947-5244515928FFQ28081678-CFCA4142-EC13-42E5-A713-CDDDC4BFAEEBQ28082612-617D2FCA-F340-42EC-AED6-218A763F36D5Q28083906-FB65C3ED-9139-4D6A-A353-7543BDDE3EC5Q28533976-01E9A776-4D61-4AAF-860D-DE880C17036FQ28743487-11D5803A-8413-4426-B4A1-B930ED6CF46CQ30419141-13B4B061-2539-4046-B388-4D4EE744B3F3Q30423207-661F712B-28AF-4233-85D4-B42301462B31Q31033689-DAB951CD-5C4D-4ACA-94BB-0879056E09ACQ33460503-523DAB8F-DA31-4D9F-9CA0-73ADE03B3C9DQ33496258-53DB3597-A2AF-48F0-843B-198DD069FBF3Q33545253-5FB9B4EE-3A87-47A8-AA04-466CDBEB85C3Q33652202-43389FDA-70BF-4E6B-9332-275C964124AAQ33691958-7E621388-67D2-4864-B27A-F94DFDE0DEC5Q33697128-68A1516D-56F9-444E-ACAE-8B5636E68445Q33747695-623B7583-C3ED-46D1-A281-EA7673D3A549Q33890707-B447A3E2-E03C-47AC-874E-74E3A8FD4B56Q33908201-8C548A79-00EF-4CA6-8AE2-5C58E21EE614Q34058311-145BFAF1-5A7D-422D-AF9A-AB4711F04716Q34094501-4F5B6986-B1AB-4689-AEAD-CC260277E106Q34130147-3771BF9B-3ADB-433B-9EAC-67112894D7FAQ34235168-FDB91237-24F2-4BEE-9733-4B41178D403BQ34430592-B1CE7CD0-EB10-44DA-86A2-33599D5ABABFQ34493230-271EAC60-3DB3-4B8B-8FFF-4AE98BB5FF55Q34575511-BEDF0255-69E5-41BF-A801-C89781BFF720Q34661343-1832E1BA-CA0D-40D4-875B-1418D9911B49Q34720291-D29FD6AF-6762-4A04-9A60-70D7F0B0A540Q34994915-AA6648BB-2046-4144-9653-F5823F5E85A1Q35001864-EDAD68FF-22D9-40EC-9341-F08C22810F29Q35171676-F1EE3C43-0B4F-41C7-B5E2-5BCE7E1F0600Q35172084-2ECD664C-8AA6-441F-AC83-9CEAB1F5648BQ35286992-0C4CE0B2-5A51-49C6-B621-1FBBDE3C452BQ35610552-7E13FBFA-8D83-4EFB-9CD8-FB4930E1A9FBQ35625868-F5090A85-4164-4CB3-BD4F-7EEF5AB05738
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Abeta-degrading enzymes in Alzheimer's disease.
@en
Abeta-degrading enzymes in Alzheimer's disease.
@nl
type
label
Abeta-degrading enzymes in Alzheimer's disease.
@en
Abeta-degrading enzymes in Alzheimer's disease.
@nl
prefLabel
Abeta-degrading enzymes in Alzheimer's disease.
@en
Abeta-degrading enzymes in Alzheimer's disease.
@nl
P2093
P2860
P1433
P1476
Abeta-degrading enzymes in Alzheimer's disease
@en
P2093
James Scott Miners
Jennifer Palmer
Laura E Palmer
Shabnam Baig
P2860
P304
P356
10.1111/J.1750-3639.2008.00132.X
P577
2008-04-01T00:00:00Z